Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

BACKGROUND: Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been approved for treatment of metastatic melanomas with a BRAF p.V600E mutation. The clinical significance of non-codon 600 mutations remains unclear, in part, due to variation of kinase activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Gang, Tseng, Li-Hui, Chen, Guoli, Haley, Lisa, Illei, Peter, Gocke, Christopher D., Eshleman, James R., Lin, Ming-Tseh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619530/
https://www.ncbi.nlm.nih.gov/pubmed/26498038
http://dx.doi.org/10.1186/s12885-015-1811-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619530/
https://www.ncbi.nlm.nih.gov/pubmed/26498038
http://dx.doi.org/10.1186/s12885-015-1811-y

Ejemplares similares